Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Share-based Compensation (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Share-based Compensation for 3 consecutive years, with $3.4 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Share-based Compensation rose 36.68% year-over-year to $3.4 million, compared with a TTM value of $14.0 million through Dec 2021, up 80.77%, and an annual FY2024 reading of $10.6 million, up 10.65% over the prior year.
  • Share-based Compensation was $3.4 million for Q4 2021 at Black Diamond Therapeutics, up from $3.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.6 million in Q2 2021 and bottomed at $91000.0 in Q1 2019.
  • Average Share-based Compensation over 3 years is $2.1 million, with a median of $2.2 million recorded in 2020.
  • Peak annual rise in Share-based Compensation hit 1962.64% in 2020, while the deepest fall reached 1.59% in 2020.
  • Year by year, Share-based Compensation stood at $2.5 million in 2019, then decreased by 1.59% to $2.5 million in 2020, then soared by 36.68% to $3.4 million in 2021.
  • Business Quant data shows Share-based Compensation for BDTX at $3.4 million in Q4 2021, $3.0 million in Q3 2021, and $4.6 million in Q2 2021.